Fibrogen enters into exclusive license for for46 with fortis therapeutics

San francisco and la jolla, calif., may 08, 2023 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) and fortis therapeutics announced that fibrogen has entered into an exclusive license with fortis therapeutics for for46, a potential first-in-class phase 1 antibody-drug conjugate (adc) targeting a novel epitope on cd46. for46 is being developed for the treatment of metastatic castration-resistant prostate cancer (mcrpc) and is being explored for use in other cd46 expressing cancers. as part of the clinical development strategy, fibrogen will continue fortis therapeutics' work to develop a pet-based biomarker utilizing a radiolabeled version of the targeting antibody (pet46) for patient selection.
FGEN Ratings Summary
FGEN Quant Ranking